Agouron ready to ship Viracept

The FDA on Friday gave its blessing to Viracept HIV protease inhibitor - less than three months after Agouron Pharmaceuticals Inc. filed its NDA - clearing the way for AGPH to put the drug on pharmacy shelves as soon as this week.

CEO Peter Johnson said the company expects to ship 21,000

Read the full 515 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE